Background & Aims Safety issues are a major concern for patients considering treatments
for inflammatory bowel disease (IBD). We performed a systematic review and meta-analysis …

Background & Aims We performed a systematic review and meta-analysis to evaluate the
comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF …

Background & Aims The risk of infection associated with tumor necrosis factor antagonists
(anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of …

Background There are limited data to inform positioning of agents for treating moderate‐
severe Crohn's disease (CD). Aim We assessed comparative efficacy and safety of first‐line …

The incidence and prevalence of Crohn's disease (CD) is rising globally. Patients with
moderate to severe CD are at high risk for needing surgery and hospitalization and for …

Cancer and autoimmune disease are closely related, and many therapeutic antibodies are
widely used in clinics for the treatment of both diseases. Among them, the anti-CD20 …

Risk of complications from specific classes of drugs for inflammatory bowel diseases (IBDs)
can be kept low by respecting contraindications. Patients with IBD frequently develop …

A subset of patients with ulcerative colitis (UC) present with, or progress to, moderate to
severe disease activity. These patients are at high risk for colectomy, hospitalization …

Crohn's disease (CD) is a chronic, disabling gastroin-testinal disease with a rising incidence
and prevalence. 1 Affecting approximately 1 in 300 people in the Western world, CD …

Background The magnitude and drivers of the risk of serious viral infections in Inflammatory
Bowel diseases (IBD) are unclear. Objective The objective of this study was to assess the …